{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:36:29Z","timestamp":1790199389696,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T00:00:00Z","timestamp":1250553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s11154-009-9111-y","type":"journal-article","created":{"date-parts":[[2009,8,17]],"date-time":"2009-08-17T05:12:42Z","timestamp":1250485962000},"page":"205-214","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacotherapy in pediatric obesity: Current agents and future directions"],"prefix":"10.1007","volume":"10","author":[{"given":"Abigail B.","family":"Wald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen K.","family":"Uli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,18]]},"reference":[{"key":"9111_CR1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","volume":"295","author":"CL Ogden","year":"2006","unstructured":"Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999\u20132004. JAMA. 2006;295:1549\u201355.","journal-title":"JAMA"},{"key":"9111_CR2","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2004-1389","volume":"90","author":"PW Speiser","year":"2005","unstructured":"Speiser PW, Rudolf MCJ, Anhalt H, et al. Consensus statement: childhood obesity. J Clin Endocrinol Metab. 2005;90:1871\u201387.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR3","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1056\/NEJMoa072515","volume":"357","author":"JL Baker","year":"2007","unstructured":"Baker JL, Olsen LW, Sorensen TIA. Childhood body mass index and the risk of coronary heart disease in adulhood. N Engl J Med. 2007;357:2329\u201337.","journal-title":"N Engl J Med."},{"key":"9111_CR4","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMsa073166","volume":"357","author":"K Bibbins-Domingo","year":"2007","unstructured":"Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357:2371\u20139.","journal-title":"N Engl J Med."},{"issue":"4","key":"9111_CR5","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1542\/peds.2007-2329C","volume":"120","author":"SE Barlow","year":"2007","unstructured":"Barlow SE, the Expert Committee. Expert Committee recommendations regarding the prevention, assessment and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(4):S164\u201392.","journal-title":"Pediatrics."},{"key":"9111_CR6","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.299.20.2401","volume":"299","author":"CL Ogden","year":"2008","unstructured":"Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003\u20132006. JAMA. 2008;299:2401\u20135.","journal-title":"JAMA."},{"key":"9111_CR7","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1542\/peds.2007-2329F","volume":"120","author":"BA Spear","year":"2007","unstructured":"Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007;120:S254\u201388.","journal-title":"Pediatrics."},{"key":"9111_CR8","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1210\/jc.2007-2458","volume":"93","author":"GP August","year":"2008","unstructured":"August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008;93:4576\u201399.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sjostrom","year":"1998","unstructured":"Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167\u201372.","journal-title":"Lancet."},{"key":"9111_CR10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","volume":"9","author":"J Hauptman","year":"2000","unstructured":"Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160\u20137.","journal-title":"Arch Fam Med."},{"key":"9111_CR11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/oby.2002.87","volume":"10","author":"JR McDuffie","year":"2002","unstructured":"McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10:642\u201350.","journal-title":"Obes Res."},{"key":"9111_CR12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1651-2227.2003.tb00596.x","volume":"92","author":"S Norgren","year":"2003","unstructured":"Norgren S, Danielsson P, Jurold R, et al. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr. 2003;92:666\u201370.","journal-title":"Acta Paediatr."},{"key":"9111_CR13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1515\/JPEM.2004.17.3.307","volume":"17","author":"JR McDuffie","year":"2004","unstructured":"McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 2004;17:307\u201319.","journal-title":"J Pediatr Endocrinol Metab."},{"key":"9111_CR14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00431-004-1534-6","volume":"163","author":"B Ozkan","year":"2004","unstructured":"Ozkan B, Bereket A, Turan S, et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163:738\u201341.","journal-title":"Eur J Pediatr."},{"key":"9111_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4158\/EP.12.1.18","volume":"12","author":"D Maahs","year":"2006","unstructured":"Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12:18\u201328.","journal-title":"Endocr Pract."},{"key":"9111_CR16","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"J-P Chanoine","year":"2005","unstructured":"Chanoine J-P, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873\u201383.","journal-title":"JAMA."},{"key":"9111_CR17","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/jc.2004-0263","volume":"90","author":"A Godoy-Matos","year":"2005","unstructured":"Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90:1460\u20135.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2006.05.008","volume":"28","author":"LM Garcia-Morales","year":"2006","unstructured":"Garcia-Morales LM, Berber A, Macias-Lara CC, et al. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controled, parallel-group trial. Clin Ther. 2006;28:770\u201382.","journal-title":"Clin Ther."},{"key":"9111_CR19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","volume":"289","author":"RI Berkowitz","year":"2003","unstructured":"Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805\u201312.","journal-title":"JAMA."},{"key":"9111_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","volume":"145","author":"RI Berkowitz","year":"2006","unstructured":"Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145:81\u201390.","journal-title":"Ann Intern Med."},{"key":"9111_CR21","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1542\/peds.107.4.e55","volume":"107","author":"M Freemark","year":"2001","unstructured":"Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.","journal-title":"Pediatrics."},{"key":"9111_CR22","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/meta.2001.28078","volume":"50","author":"JP Kay","year":"2001","unstructured":"Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457\u201361.","journal-title":"Metabolism."},{"key":"9111_CR23","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2006-0241","volume":"91","author":"S Srinivasan","year":"2006","unstructured":"Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074\u201380.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1399-5448.2008.00434.x","volume":"9","author":"TS Burgert","year":"2008","unstructured":"Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567\u201376.","journal-title":"Pediatr Diabetes."},{"key":"9111_CR25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jpeds.2008.01.018","volume":"152","author":"K Love-Osborne","year":"2008","unstructured":"Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin. J Pediatr. 2008;152:817\u201322.","journal-title":"J Pediatr."},{"key":"9111_CR26","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1210\/jc.2004-0376","volume":"89","author":"WT Gibson","year":"2004","unstructured":"Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the delta-133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89:4821\u20136.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR27","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jpeds.2004.08.002","volume":"145","author":"A Carrel","year":"2004","unstructured":"Carrel A, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744\u20139.","journal-title":"J Pediatr."},{"key":"9111_CR28","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1210\/jc.2002-030003","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586\u201392.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR29","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"J-P Despres","year":"2005","unstructured":"Despres J-P, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121\u201334.","journal-title":"N Engl J Med."},{"key":"9111_CR30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761\u201375.","journal-title":"JAMA."},{"key":"9111_CR31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","volume":"23","author":"FA Moreira","year":"2009","unstructured":"Moreira FA, Grieb M, Lutz B. Central side effects of therapies based on CB1 cannabinoid receptor agonist and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009;23:133\u201344.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"Suppl 1","key":"9111_CR32","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1177\/0883073800015001S05","volume":"15","author":"PM Levisohn","year":"2000","unstructured":"Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol. 2000;15(Suppl 1):S22\u20136.","journal-title":"J Child Neurol."},{"key":"9111_CR33","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4088\/JCP.v68n0901","volume":"68","author":"AM Claudino","year":"2007","unstructured":"Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68:1324\u201332.","journal-title":"J Clin Psychiatry."},{"key":"9111_CR34","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","volume":"289","author":"KM Gadde","year":"2003","unstructured":"Gadde KM, Franciscy DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820\u20135.","journal-title":"JAMA."},{"key":"9111_CR35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"DM Kendall","year":"2005","unstructured":"Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30\u00a0weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083\u201391.","journal-title":"Diabetes Care."},{"key":"9111_CR36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30\u00a0weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092\u2013100.","journal-title":"Diabetes Care."},{"key":"9111_CR37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","volume":"10","author":"JW Anderson","year":"2002","unstructured":"Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10:633\u201341.","journal-title":"Obes Res."},{"key":"9111_CR38","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/oby.2002.142","volume":"10","author":"AK Jain","year":"2002","unstructured":"Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049\u201356.","journal-title":"Obes Res."},{"key":"9111_CR39","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/jc.2006-2409","volume":"93","author":"L McGovern","year":"2008","unstructured":"McGovern L, Johnson JN, Paulo R, et al. Treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab. 2008;93:4600\u20135.","journal-title":"J Clin Endocrinol Metab."},{"key":"9111_CR40","first-page":"CD001872","volume":"1","author":"H Oude Luttikhuis","year":"2009","unstructured":"Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database Syst Rev. 2009;1:CD001872.","journal-title":"Cochrane Database Syst Rev."},{"key":"9111_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MED.0b013e3282f41d6a","volume":"15","author":"N Uli","year":"2008","unstructured":"Uli N, Sundararajan S, Cuttler C. Treatment of childhood obesity. Curr Opin Endocrinol Diabetes Obes. 2008;15:37\u201347.","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"9111_CR42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2337\/dc06-1569","volume":"30","author":"M Freemark","year":"2007","unstructured":"Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care. 2007;30:395\u2013402.","journal-title":"Diabetes Care."}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-009-9111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-009-9111-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-009-9111-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T08:31:22Z","timestamp":1559377882000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-009-9111-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,18]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["9111"],"URL":"https:\/\/doi.org\/10.1007\/s11154-009-9111-y","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,18]]}}}